✦ LIBER ✦

Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia

✍ Scribed by Wiernik, Peter H.; Adiga, Giridhar U.

Book ID: 111917074
Publisher: Informa plc
Year: 2011
Tongue: English
Weight: 187 KB
Volume: 27
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007995.2011.615307

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab plus cladribine with or withou

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

✍ Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Olga Grzybowska-Izydorczyk; Jerz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 543 KB

The successful treatment of refractory a

The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia

✍ Gülsüm Emel Pamuk; Burhan Turgut; Muzaffer Demir; Fatma Tezcan; Özden Vural 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

Bendamustine Combined With Rituximab in

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

✍ Fischer, K.; Cramer, P.; Busch, R.; Stilgenbauer, S.; Bahlo, J.; Schweighofer, C 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 141 KB

Effective treatment with rituximab in a

Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome

✍ G. Seipelt; A. Böhme; S. Koschmieder; D. Hoelzer 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 40 KB

Rituximab in combination with high-dose

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia

✍ Lukáš Smolej; Michael Doubek; Anna Panovská; Martin Šimkovič; Yvona Brychtová; D 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Phase II study of single-agent bortezomi

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

✍ Stefan Faderl; Kanti Rai; John Gribben; John C. Byrd; Ian W. Flinn; Susan O'Brie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views